Table 4.

Response of uveitis and arthritis activity to abatacept (ABA) treatment in patients with severe uveitis associated with juvenile idiopathic arthritis (n = 21 patients).

Pt.	Uveitis Activity after ABA	Months until Uveitis Inactivity	Uveitis Recurrences after Achieving Inactivity	Arthritis Activity^* prior to ABA	Arthritis Activity^* at End of Followup	Followup, mos
1	Inactive	6	Yes	Yes	Inactive	12
2	Inactive	6	Yes	Yes	Active	12
3	Inactive	6	Yes	Yes	Active	12
4	Active	—	Ongoing	Yes	Active	6^*
5	Active	—	Ongoing	Yes	Inactive	12
6	Inactive	6	Yes	Yes	Active	9^**
7	Inactive	9	No	Yes	Inactive	12
8	Active	—	Ongoing	Yes	Active	6^**
9	Inactive	3	Yes	Yes	Active	6^**
10	Inactive	6	Yes	Yes	Active	12
11	Inactive	9	Yes	Yes	Inactive	12
12	Inactive	9	No	Yes	Active	12
13	Active	—	Ongoing	Yes	Active	6^**
14	Inactive	6	No	Yes	Inactive	12
15	Inactive	3	Yes	Yes	Active	9^**
16	Active	—	Ongoing	No	Inactive	6^**
17	Active	—	Ongoing	No	Inactive	12^**
18	Active	—	Ongoing	Yes	Inactive	6^**
19	Active	—	Ongoing	Yes	Inactive	3
20	Active	—	Ongoing	Yes	ND	12
21	Active	—	Ongoing	ND	ND	12

Uveitis activity determined according to Standardization of Uveitis Nomenclature Working Group criteria²³.
↵* Arthritis activity determined by American College of Rheumatology Pediatric30/50/70 criteria²⁵.
↵** Premature study end because of treatment failure. ND: no data.